Humanin (HN) is a 24 amino acid mitochondrial derived peptide encoded within the MTRNR2 region of mitochondrial DNA, a short open reading frame inside the 16S ribosomal RNA gene. It was first described in 2001, cloned from surviving neurons in Alzheimer’s brain tissue. Circulating levels decline with age in humans, and the peptide is conserved across worms, mice, primates, and people, where greater availability has tracked with stress resistance and longevity in model systems.

This lesson examines the preclinical and translational evidence so clinicians can place humanin accurately on the spectrum of known, emerging, and uncertain. Several analogs are discussed, including HNG, reported as roughly a thousand times more potent than native humanin, and HNGF6A, which removes IGF binding protein 3 binding to enhance metabolic effects.

Mechanism and receptor signaling

Humanin acts both inside and outside the cell. It is secreted via a pseudo signaling peptide and detected in plasma, CSF, and tissue. Two receptors are described: the CNTFR/WSX1/GP130 trimeric complex, which drives JAK2/STAT3, ERK, and PI3K/AKT signaling tied to cytoprotection and anti apoptosis, and FPRL1, which the peptide competitively antagonizes. Intracellularly, humanin sequesters BAX in the cytoplasm to block its translocation into mitochondria, and it antagonizes IGF binding protein 3, both reducing intrinsic apoptosis.

Therapeutic domains under study

The transcript groups the preclinical signals into several areas, with mechanisms confirmed largely in animal and in vitro work:

• Neuroprotection: chaperone activity against amyloid beta oligomerization, STAT3 driven survival signaling, and reduced microglial inflammatory cytokines.
• Cardioprotection: AMPK/eNOS signaling, with HNG associated with a 50 percent reduction in cardiac infarct size in myocardial ischemia reperfusion models.
• Metabolic regulation: central, hypothalamic STAT3 mediated insulin sensitization and chaperoning of IAPP misfolding relevant to beta cell stress.
• Retinal protection: in vitro protection of retinal pigment epithelial cells from oxidative and mitochondrial stress.

Limits, safety, and clinical status

Human cognitive, cardiovascular, and metabolic data remain observational or correlative. A phase one study in healthy volunteers at a single IV dose reported no adverse ECG or laboratory findings, with mild headache noted; no phase two or three trials exist. The native peptide has a short half life of about five to fifteen minutes, which complicates systemic use and motivates work on pegylation, nanoparticles, and sustained release. Much published efficacy data reflect the HNG analog, so extrapolation to native humanin is unvalidated.

Key clinical points

• Humanin is a mitochondrial derived peptide encoded by MTRNR2; circulating levels decline with age, and children of centenarians show elevated production.
• Core mechanisms span BAX sequestration, STAT3 and PI3K/AKT survival signaling, AMPK/eNOS cardioprotection, and amyloid chaperone activity.
• The evidence base is preclinical and translational; no randomized controlled human trials and no established dosing or long term safety data exist.
• The same anti apoptotic mechanism raises a theoretical concern in active or prior malignancy, which the speaker frames as a contraindication pending data.
• Humanin is not FDA approved and is positioned as a research peptide; any clinical use is investigational and off label, requiring informed consent.